On August 22, 2022, Innoviva Inc. (the Parent) completed the previously announced acquisition of La Jolla Pharmaceutical Company (the Company), pursuant to an Agreement and Plan of Merger, dated as of July 10, 2022 (Merger Agreement), by and among the Company, Parent and Innoviva Acquisition Sub Inc. (the Purchaser). In accordance with the terms of the Merger Agreement: (i) each of Kevin Tang, Larry Edwards, Craig Johnson, Laura Johnson, David Ramsay and Robert Rosen resigned from his or her respective position as a member of the Company's Board of Directors, and any committee thereof, effective at the Effective Time (as defined in the Merger Agreement); and (ii) Kevin Tang, resigned from his position as Chairman of the Company's Board of Directors. Effective as of the Effective Time: (i) Pavel Raifeld, CFA, and Marianne Zhen, CPA, became members of the Company's Board of Directors; (ii) Larry Edwards will remain Chief Executive Officer and President, and principal executive officer, as such term is defined under the Exchange Act, of the Company; and (iii) Michael Hearne will remain Chief Financial Officer, and principal financial officer and principal accounting officer, as such terms are defined under the Exchange Act, of the Company.
La Jolla Pharmaceutical Company
Equities
LJPC
US5034596040
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |